Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:47:02 EDT Sat 05 Jul 2025
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
News for U:XFOR from 2024-07-05 to 2025-07-04 - 29 items
News Releases
In The News
Other
CA
US
Date
Sym
Price
Type
Headline
2025-06-16 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)
2025-06-10 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA
2025-06-02 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-14 16:12
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
2025-05-01 06:01
U
U:XFOR
News Release
200
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
2025-04-24 08:03
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025
2025-04-24 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Reverse Stock Split
2025-04-23 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-25 06:01
U
U:XFOR
News Release
200
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
2025-03-11 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
2025-02-19 07:35
U
U:XFOR
News Release
200
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI(TM) (mavorixafor) in WHIM Syndrome in Select Middle East Countries
2025-02-06 07:35
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
2025-02-03 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-24 07:36
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome
2025-01-13 07:35
U
U:XFOR
News Release
200
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
2024-12-04 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition
2024-12-03 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-11-26 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference
2024-11-14 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
2024-11-13 06:07
U
U:XFOR
News Release
200
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
2024-11-13 06:01
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)
2024-11-01 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-10-24 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024
2024-10-01 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-03 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-28 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences
2024-08-08 06:01
U
U:XFOR
News Release
200
X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
2024-08-01 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-07-30 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024